These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 31382929)

  • 21. A population-based analysis of germline BAP1 mutations in melanoma.
    O'Shea SJ; Robles-Espinoza CD; McLellan L; Harrigan J; Jacq X; Hewinson J; Iyer V; Merchant W; Elliott F; Harland M; Bishop DT; Newton-Bishop JA; Adams DJ
    Hum Mol Genet; 2017 Feb; 26(4):717-728. PubMed ID: 28062663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the CDKN2A locus in patients with multiple primary melanomas.
    Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
    J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
    Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
    Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease.
    Wu J; Wang H; Ricketts CJ; Yang Y; Merino MJ; Zhang H; Shi G; Gan H; Linehan WM; Zhu Y; Ye D
    Cancer; 2019 Apr; 125(7):1060-1069. PubMed ID: 30548481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
    van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
    Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
    Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
    Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
    Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
    Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDKN2A mutations in multiple primary melanomas.
    Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
    N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline mutations predisposing to melanoma.
    Toussi A; Mans N; Welborn J; Kiuru M
    J Cutan Pathol; 2020 Jul; 47(7):606-616. PubMed ID: 32249949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
    Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
    Potjer TP; Bollen S; Grimbergen AJEM; van Doorn R; Gruis NA; van Asperen CJ; Hes FJ; van der Stoep N;
    Int J Cancer; 2019 May; 144(10):2453-2464. PubMed ID: 30414346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.
    Casula M; Muggiano A; Cossu A; Budroni M; Caracò C; Ascierto PA; Pagani E; Stanganelli I; Canzanella S; Sini M; Palomba G; ; Palmieri G
    BMC Cancer; 2009 Oct; 9():352. PubMed ID: 19799798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
    van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
    J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Increased knowledge on familial melanoma and the underlying genetics].
    Helgadottir H; Nielsen K; Höiom V
    Lakartidningen; 2017 May; 114():. PubMed ID: 28485764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
    Zauderer MG; Jayakumaran G; DuBoff M; Zhang L; Francis JH; Abramson DH; Cercek A; Nash GM; Shoushtari A; Chapman P; D'Angelo S; Arnold AG; Siegel B; Fleischut MH; Ni A; Rimner A; Rusch VW; Adusumilli PS; Travis W; Sauter JL; Zehir A; Mandelker D; Ladanyi M; Robson M
    J Thorac Oncol; 2019 Nov; 14(11):1989-1994. PubMed ID: 31323388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
    Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors.
    Garfield EM; Walton KE; Quan VL; VandenBoom T; Zhang B; Kong BY; Isales MC; Panah E; Kim G; Gerami P
    J Am Acad Dermatol; 2018 Sep; 79(3):525-534. PubMed ID: 29753057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
    Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
    J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel and recurrent p14 mutations in Italian familial melanoma.
    Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
    Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.